"YuanSi ShengTai" completes Series B financing

36Kr learned that "YuanSi ShengTai" announced the completion of its Series B financing. It was led by an international biotechnology fund, with co-leads from Decheng Capital and Dinghui VGC, along with follow-on investments from a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA), Temasek's wholly-owned subsidiary Dama Capital, Qiming Venture Partners, Boyuan Capital, and other well-known industry investment institutions. Meanwhile, existing shareholders such as AstraZeneca, Eli Lilly Asia Fund, Innovation Works, Wuyuan Capital, Hillhouse Ventures (GL Ventures), Biotech Development Fund, and Lenovo Capital continue to increase their stakes. The funds will be primarily used to deepen the intelligent iteration of its self-developed macrocyclic peptide discovery platform Synova™ and accelerate the conversion of the company's diversified innovative drug pipeline into clinical stages